Posted by Michael Wonder on 18 Feb 2021
Fresenius Kabi Canada launches Idacio (adalimumab injection) a biosimilar to Humira (adalimumab) for the treatment of multiple chronic inflammatory conditions
18 February 2021 - Biosimilars offer patients access to affordable, meaningful medicines
Fresenius Kabi Canada announced today it has introduced Idacio, an adalimumab biosimilar, in Canada. The drug is available immediately for all indications of the reference medicine in the areas of rheumatology, gastro-enterology and dermatology.
Idacio received marketing authorisation from Health Canada on 30 October 2020 and is the first biosimilar product introduced in North America by Fresenius Kabi.
